Cover Image

Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML

Abstract KMT2A-rearranged acute myeloid leukemia (KMT2Ar-AML) is an aggressive subtype of AML with poor response and prognosis. KMT2Ar-AML has been demonstrated to be sensitive to BCL2 inhibitor venetoclax (VEN), but these patients are unable to benefit from current VEN-based regimen (VEN plus azaci...

Full description

Saved in:

Bibliographic Details
Main Authors:	Qing Ling (Author), Yutong Zhou (Author), Yu Qian (Author), Jiejing Qian (Author), Yi Zhang (Author), Jinghan Wang (Author), Yanan Zhu (Author), Yile Zhou (Author), Juying Wei (Author), Chunmei Yang (Author), Jie Sun (Author), Wenjuan Yu (Author), Jie Jin (Author), Xiang Zhang (Author)
Format:	Book
Published:	BMC, 2023-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
by: Xiang Zhang, et al.
Published: (2021)

Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia
by: Claudia Tregnago, et al.
Published: (2022)

Meninės gimnastikos sportininkių varžybų laikotarpio rengimo ir parengtumo sąveika
by: Renata Rutkauskaitė
Published: (2018)

Menin Coordinates C/EBPβ-Mediated TGF-β Signaling for Epithelial-Mesenchymal Transition and Growth Inhibition in Pancreatic Cancer
by: Peng Cheng, et al.
Published: (2019)

The Protective Effect of Sericin on AML12 Cells Exposed to Oxidative Stress Damage in a High-Glucose Environment
by: Feng-Ya Jing, et al.
Published: (2022)

Case report of kabuki syndrome in a newborn caused by KMT2D gene mutation
by: Xuejiao Ba, et al.
Published: (2024)

Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript
by: Sophie Voruz, et al.
Published: (2021)

Magnolol Inhibits High Fructose-Induced Podocyte Inflammation via Downregulation of TKFC/Sp1/HDAC4/Notch1 Activation
by: Ziang Zhou, et al.
Published: (2024)

Venetoclax: evidence to date and clinical potential
by: Luis Miguel Juárez-Salcedo, et al.
Published: (2019)

Development of venetoclax for therapy of lymphoid malignancies
by: Zhu H, et al.
Published: (2017)

Bleomycin induces senescence and repression of DNA repair via downregulation of Rad51
by: Fuqiang Chen, et al.
Published: (2024)

The Partial Duplication of the 5' Segment of KMT2A Revealed KMT2A-MLLT10 Rearrangement in a Boy with Acute Myeloid Leukemia
by: Hiroko Fukushima, et al.
Published: (2017)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
by: Elizabeth A. Thomas
Published: (2014)

Increased METTL3-mediated m6A methylation inhibits embryo implantation by repressing HOXA10 expression in recurrent implantation failure
by: Pingping Xue, et al.
Published: (2021)

MicroRNA-mRNA Pairs Associated with Outcome in AML: From in vitro Cell-based Studies to AML Patients
by: Neha S Bhise, et al.
Published: (2016)

Population Pharmacokinetic Models of Venetoclax in Hematologic Malignancies: A Systematic Review
by: Zhao Y, et al.
Published: (2024)

Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin
by: Ali A. Alhadab, et al.
Published: (2020)

On the Stability and Degradation Pathways of Venetoclax under Stress Conditions
by: Nina Žigart, et al.
Published: (2020)

Targeted Therapies for Pediatric AML: Gaps and Perspective
by: Annalisa Lonetti, et al.
Published: (2019)

Refining the Phenotypic Spectrum of KMT5B-Associated Developmental Delay
by: Aviva Eliyahu, et al.
Published: (2022)

CNST is Characteristic of Leukemia Stem Cells and is Associated With Poor Prognosis in AML
by: Haoyu Liu, et al.
Published: (2022)

Identification of STAB1 in Multiple Datasets as a Prognostic Factor for Cytogenetically Normal AML: Mechanism and Drug Indications
by: Sheng-Yan Lin, et al.
Published: (2019)

Novel KMT2B gene mutation in MUC4 positive low-grade fibromyxoid sarcoma
by: Liying Zhang, et al.
Published: (2024)

Circ_0099630 Participates in SPRY1-Mediated Repression in Periodontitis
by: Jing Wang, et al.
Published: (2023)

KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors
by: Rui Zhang, et al.
Published: (2020)

Synergistic effect of venetoclax and teglicar in multiple myeloma cell lines
by: Belal A. Al-Husein, et al.
Published: (2024)

Supersaturated Lipid-Based Formulations to Enhance the Oral Bioavailability of Venetoclax
by: Niklas J. Koehl, et al.
Published: (2020)

YTHDF2, a protein repressed by miR-145, regulates proliferation, apoptosis, and migration in ovarian cancer cells
by: Jie Li, et al.
Published: (2020)

Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias
by: Bruno A. Lopes, et al.
Published: (2022)

Dysregulated transcriptional networks in KMT2A- and MLLT10-rearranged T-ALL
by: Huining Kang, et al.
Published: (2018)

AML in the Molecular Age: From Biology to Clinical Management
by: Celalettin Ustun (Ed.)
Published: (2018)

Biomarkers as targets for CAR-T/NK cell therapy in AML
by: Ruonan Shao, et al.
Published: (2023)

Transformation of CMML to AML presenting with acute kidney injury
by: Rebecca DeBoer, et al.
Published: (2020)

A novel deletion mutation in KMT2A identified in a child with ID/DD and blood eosinophilia
by: Haixia Zhang, et al.
Published: (2019)

Wiedemann-Steiner Syndrome with a Pathogenic Variant in <i>KMT2A</i> from Taiwan
by: Chung-Lin Lee, et al.
Published: (2021)

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review
by: Qiang Cao, et al.
Published: (2023)

Hyperoxia exposure induces ferroptosis and apoptosis by downregulating PLAGL2 and repressing HIF-1α/VEGF signaling pathway in newborn alveolar typeII epithelial cell
by: Yuting Zhu, et al.
Published: (2024)

Effects of structurally distinct human HDAC6 and HDAC6/HDAC8 inhibitors against S. mansoni larval and adult worm stages.
by: Roberto Gimmelli, et al.
Published: (2024)

Model‐Informed Dosing of Venetoclax in Healthy Subjects: An Exposure−Response Analysis
by: Nimita Dave, et al.
Published: (2019)

Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
by: Simona De Gregori, et al.
Published: (2023)